Children below the age of 15 years account for about 10 to 12 per cent of India's overall TB burden.
There are also lingering concerns over the culture of misuse of pharmaceutical products in India, which has, in the past, led to other drugs becoming increasingly ineffective.
US-based pharmaceutical major Eli Lilly on Thursday announced a $70 million initiative as part of its effort to combat the spread of Multi-Drug Resistant Tuberculosis in India and other developing countries.
The World Health Organization's Global Tuberculosis Report 2014, published recently shows that 9 million people developed TB in 2013, and 1.5 million died, revealing that there are almost half a million more cases of the disease than previously estimated.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances